Mavacamten fda approval date?

What was the FDA approval date for mavacamten?

Mavacamten (Camzyos) received FDA approval on April 26, 2022 [1].

What is mavacamten (Camzyos) approved for?

Camzyos is approved for adults with symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms [1].

When did it first receive FDA review/marketing authorization?

The FDA’s approval date is the date marketing authorization was granted; for mavacamten, that date was April 26, 2022 [1].

Sources

1